Instruction for use: Pentoxifylline Rivo

Dosage form: Tablets of prolonged action, enteric coated; Enteric coated tablets

Active substance: Pentoxyphyllinum

ATX

C04AD03 Pentoxifylline

Pharmacological group

Antiaggregants

Adenosinergic agents

Angioprotectors and microcirculation correctors

The nosological classification (ICD-10)

G58 Other mononeuropathies: Mononeuropathies

G59 Mononeuropathy in diseases classified elsewhere

G93.4 Unspecified Encephalopathy: bilirubin encephalopathy; lacunarity status; Tremor when portal-systemic encephalopathy; The latent hepatic encephalopathy; Atherosclerotic encephalopathy; Hypertensive encephalopathy; hypoxic encephalopathy; dismetabolic encephalopathy; Encephalopathy; brain lesion; Porto-caval encephalopathy; Vascular encephalopathy; Traumatic encephalopathy; encephalopathy; encephalopathy; Encephalopathy secondary genesis; Encephalopathy discirculatory; Encephalopathy portocaval; epileptic encephalopathy; hemorrhagic shock and encephalopathy syndrome; Subacute spongiform encephalopathy

H34 Vascular occlusion of retina: Arterial thrombosis of the vessels of the eye; Venous thrombosis of the vessels of the eye; Violation of retinal circulation; Disturbances of intraocular circulation; Insufficient blood supply to the mesh and choroid; Occlusion of central retinal vessels; Acute obstruction of retinal arteries; Subacute and chronic circulatory insufficiency in the retina or in the choroid of the eye; Vascular diseases of the retina; Vascular disorders in the retina of the eye; Vascular thrombosis of the retina; Central retinal vein thrombosis; Thrombosis of the central vein of the retina and its branches; Thrombosis of the central vein of the retina of the eye and its branches

H35.3 Macular and posterior pole degeneration: Macular degeneration; Retinal dystrophy; Angiosclerotic maculodystrophy; Age-related macular degeneration; Age-related macular degeneration; Nontranssudative forms of macular degeneration; Degenerative changes of a yellow stain; Stargardt's disease; Degenerative processes in the yellow spot; Retinal degeneration; Macular degeneration; Pigmented degeneration of the retina; Macular degeneration age (senile); Dystrophy of the mesh membrane; Hereditary pigmentary degeneration of the retina; Hereditary taperoteretal degenerations; Older macular degeneration

H83 Other internal ear disorders: Disturbance of inner ear function; Violation of the inner ear function of vascular genesis; Disturbances of blood supply to the inner ear; Functional disorder of the inner ear

H91 Other hearing loss: Age-related vascular hearing loss; Age-related vascular drop in hearing; Age-related hearing impairment; Idiopathic hearing loss; Decreased acuity of hearing; Hearing loss; Deteriorating hearing of vascular or toxic origin; Perceptual hearing loss

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I70 Atherosclerosis: Atherosclerosis; Atherosclerosis of peripheral vessels; Atherosclerotic changes; Atherosclerotic vascular changes; Atherosclerotic disorders; spontaneous; Trombangioz obliterans; Frinlendera disease

I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans

I73.0 Raynaud's Syndrome: Raynaud's syndrome Leriche; Raynaud's disease; Raynaud's phenomenon; RaynaudLeriche syndrome; Raynaud's disease; Raynaud's syndrome with trophic disorders; Peripheral angiopathy

I79.2 Peripheral angiopathy in diseases classified elsewhere: diabetic angiopathy; Angiopathy in diabetes; arteriosclerosis diabetic; Pain in lesions of peripheral nerves; Diabetic angiopathy; Diabetic microangiopathy; Diabetic vascular disease; Intermittent angioneurotic disbaziya; Macroangiopathy in diabetes; microangiopathy; Microangiopathy in diabetes mellitus; Tingling sensations in the hands and feet; Coldness in the extremities; Peripheral angiopathy; Peripheral arterial disease; Sclerosis Menkeberga; Chronic obliterating diseases of arteries

I87.0 Postphlebitic syndrome: post-thrombotic venous insufficiency; Postthrombotic disease; Post thrombophlebitic syndrome; Post-thrombophlebitis; Post-thrombophlebitic syndrome; Postphlebitic syndrome; Post thrombotic syndrome; Postphlebitic syndrome (stasis syndrome)

I99 Other and unspecified disorders of the circulatory system: angiopathy; Arterial angiopathy; Atherosclerotic angiopathy; Hemodynamic right heart defects; Hemodynamic defect of the right heart; coronary angiopathy; Infringement of blood circulation; Violation of circulation; Violation microcirculation in organs and tissues; Peripheral circulatory disorders; Disorders of the peripheral circulation in the extremities; circulatory failure; Hemodynamic instability occlusion of arteriovenous origin; Acute circulatory failure; Psevdostenokardicheskie state; Psevdostenokardicheskoe disorder; circulatory disorder; Cardiovascular diseases; Vascular insufficiency; Thrombosis arteriovenous shunt; Thrombosis with prosthetic heart valves; Deterioration of blood circulation in the pelvic organs; Functional failure of the cardiovascular system; Functional disorders of the cardiovascular system; Chronic arterial insufficiency; Chronic heart failure; Age-related vascular disease; The risk of thrombosis

L87 Transepidermal perforations

T33-T35 Frostbite

Composition and release form

1 enteric coated tablet contains pentoxifylline 100 mg; In a cardboard box 6 blisters for 10 pcs.

1 retard coated tablet with enteric 400 mg; In a cardboard box 2 blisters for 10 pcs.

Pharmacology

Mode of action - Vasodilator, antiaggregational, improving microcirculation.

It blocks adenosine receptors, inhibits phosphodiesterase, promotes the accumulation of cAMP in cells.

Pharmacodynamics

It improves microcirculation and rheological properties of blood, dilates blood vessels, improves oxygen supply to tissues, reduces platelet aggregation, increases erythrocyte elasticity, reduces blood viscosity.

Pharmacokinetics

When ingested quickly and fully absorbed, Cmax pentoxifylline and its metabolites is achieved after 2-4 hours, a stable level is maintained in the blood for 12 hours.

Indications of Pentoxifylline Rivo

Atherosclerotic and discirculatory encephalopathy, ischemic cerebral stroke, peripheral circulatory disorders due to atherosclerosis, diabetes, inflammation, diabetic angiopathy, obliterating endarteritis, trophic disorders (post-phlebitis syndrome, trophic ulcers, gangrene, frostbite), angioneuropathy (paresthesia, Raynaud's disease), insufficiency Blood circulation of the retina and mucous membrane of the eye, a violation of the inner ear function, accompanied by deafness.

Contraindications

Hypersensitivity, acute myocardial infarction, massive bleeding, cerebral hemorrhage, hemorrhage in the retina of the eye, pregnancy.

Side effects

Nausea, vomiting, a feeling of heaviness in the epigastrium, diarrhea; Headache, dizziness, tachycardia, hyperemia of the face, angina, arterial hypotension, bleeding from the vessels of the skin and mucous membranes, skin rashes, itching, urticaria.

Dosage and Administration

Inside, not chewing, drinking water for 100-500 mg 3 times a day.

Precautionary measures

During treatment, the blood pressure level should be monitored. With caution combine with antihypertensive drugs, oral antidiabetic drugs, insulin, anticoagulants.

Storage conditions of Pentoxifylline Rivo

In the dark place at a temperature of 15-25 ° C.

Keep out of the reach of children.

Shelf life

3 years

Do not use beyond the expiration date printed on the package.